Seattle Genetics (SGEN) Set to Announce Quarterly Earnings on Wednesday

Seattle Genetics (NASDAQ:SGEN) is scheduled to issue its quarterly earnings data after the market closes on Wednesday, April 25th. Analysts expect the company to announce earnings of ($0.42) per share for the quarter.

Seattle Genetics (NASDAQ:SGEN) last posted its quarterly earnings results on Tuesday, February 6th. The biotechnology company reported ($0.41) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.02. The business had revenue of $129.61 million during the quarter, compared to analyst estimates of $123.99 million. Seattle Genetics had a negative return on equity of 32.49% and a negative net margin of 26.03%. The business’s revenue was up 23.1% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.39) earnings per share. On average, analysts expect Seattle Genetics to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

How to Become a New Pot Stock Millionaire

SGEN stock opened at $49.68 on Monday. The company has a market capitalization of $7,857.39, a PE ratio of -56.45 and a beta of 1.84. Seattle Genetics has a 1 year low of $45.31 and a 1 year high of $71.32.



In related news, insider Clay B. Siegall sold 18,832 shares of the company’s stock in a transaction that occurred on Friday, February 9th. The stock was sold at an average price of $49.75, for a total value of $936,892.00. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Vaughn B. Himes sold 5,000 shares of the company’s stock in a transaction that occurred on Thursday, March 15th. The shares were sold at an average price of $58.12, for a total value of $290,600.00. The disclosure for this sale can be found here. Insiders sold 71,953 shares of company stock worth $3,810,778 over the last quarter. 33.80% of the stock is currently owned by insiders.

SGEN has been the subject of a number of analyst reports. Needham & Company LLC restated a “buy” rating and issued a $74.00 price target (up from $72.00) on shares of Seattle Genetics in a research report on Wednesday, February 7th. HC Wainwright restated a “buy” rating on shares of Seattle Genetics in a research report on Wednesday, February 7th. Royal Bank of Canada restated a “buy” rating and issued a $73.00 price target on shares of Seattle Genetics in a research report on Tuesday, March 20th. TheStreet lowered Seattle Genetics from a “c-” rating to a “d+” rating in a research report on Wednesday, February 28th. Finally, JPMorgan Chase restated a “hold” rating on shares of Seattle Genetics in a research report on Tuesday, January 9th. One investment analyst has rated the stock with a sell rating, nine have given a hold rating and ten have given a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus price target of $64.00.

ILLEGAL ACTIVITY WARNING: “Seattle Genetics (SGEN) Set to Announce Quarterly Earnings on Wednesday” was first reported by StockNewsTimes and is the property of of StockNewsTimes. If you are accessing this piece of content on another website, it was stolen and reposted in violation of U.S. & international copyright law. The original version of this piece of content can be viewed at https://stocknewstimes.com/2018/04/23/seattle-genetics-sgen-set-to-announce-quarterly-earnings-on-wednesday.html.

About Seattle Genetics

Seattle Genetics, Inc, a biotechnology company, focuses on the development and commercialization of targeted therapies for the treatment of cancer worldwide. It markets ADCETRIS, an antibody-drug conjugate for the treatment of relapsed Hodgkin lymphoma and relapsed systemic anaplastic large cell lymphoma.

Earnings History for Seattle Genetics (NASDAQ:SGEN)

Receive News & Ratings for Seattle Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seattle Genetics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply